A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide
- Indications Hepatitis C; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Co-STARs
- Sponsors Gilead Sciences
- 04 Oct 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2017 Planned End Date changed from 29 Sep 2017 to 1 Oct 2017.
- 02 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 1 Sep 2017.